Neoantigen Discovery: Realizing the Promise of Personalized Treatment
Originally Aired April 18, 2019
Advances in next-generation sequencing technology and computational data analysis have revolutionized efforts to identify tumor-specific mutant antigens. These altered, potentially immunogenic proteins may prove to be an important target for immunotherapies. In this Cell Press Webinar, Nicholas McGranahan (University College London) and Gerald Linette (University of Pennsylvania) will review progress made and future applications of this important area of cancer immunogenomics.
Nicholas McGranahan Group Leader, Cancer Genome Evolution Research Group University College London View Biography
Gerald P. Linette Parker Institute for Cancer Immunotherapy Center for Cellular Immunotherapies Perelman School of Medicine University of Pennsylvania View Biography
Moderator: Jiaying Tan Senior Scientific Editor Cell